Prexige (Lumiracoxib) - COX-2 Selective Inhibitor - Drug Information
Prexige (lumiracoxib) is a COX-2 selective inhibitor medication currently in development by Novartis. Drug information on the COX-2 selective inhibitor Prexige, generic drug name lumiracoxib. Prexige (lumiracoxib) has been approved in the United Kingdom. Prexige (lumiracoxib) is slated for approval in the United States in 2007.
- A - Z: Arthritis Drugs
- A - Z: Drug Costs
- A - Z: NSAIDs
- COX-2 Selective Inhibitors
- Inflammation
- Joint Pain
- Pain Relief
10/03/2007: FDA Deems Arthritis Medicine Prexige "Not Approvable"
Prexige (lumiracoxib), a medicine being developed by Novartis as a once-daily treatment for arthritis patients with osteoarthritic pain, has not been approved by the U.S. Food and Drug Administration (FDA). On September 27, 2007, Novartis received a "not approvable" letter from the FDA.
10/3/2007 - Prexige Withdrawn in Canada / USA Does Not Approve Prexige
Australia and Canada have withdrawn Prexige from the market citing liver complications. The U.S. has decided not to approve Prexige.
What Are COX-2 Inhibitors?
A brief explanation and fast facts about the COX-2 inhibitors.
Arthritis Drugs: What Are My Options?
Medications have long been considered "traditional" treatment. Since individual response to a specific medication can vary and because possible side effects are also a factor, finding the most effective medication or combination of medications can be a more difficult process than one would expect.
